Intracerebral hemorrhage
ICD-10 I61 · ICD-11 8B00

Treatment of Spontaneous Intracerebral Hemorrhage in Patients on a Direct Factor Xa Inhibitor

Spontaneous intracerebral hemorrhage occurring in a patient actively treated with a direct factor Xa inhibitor — rivaroxaban, apixaban, or edoxaban — represents an emergency that requires immediate, structured anticoagulation reversal to limit hematoma expansion.

Clinical scenario

The patient presents with spontaneous ICH while receiving a direct factor Xa inhibitor (rivaroxaban, apixaban, or edoxaban). Ongoing anticoagulant activity at the time of hemorrhage directly threatens haematoma stability and must be counteracted as a priority.

Treatment goals
  • Reduced anti–factor Xa activity
  • Excellent or good haemostatic outcome: <35% increase in hematoma volume at 12 hours
Approach — partial overview

Management centres on immediate anticoagulation discontinuation and urgent reversal of factor Xa inhibitor activity using specific reversal agents; additional haemostatic and drug-absorption measures may be indicated depending on timing and agent availability. The complete sequenced protocol is available below.

Instant Access to Structured Evidence-Based Regimens

References

In patients with anticoagulant-associated spontaneous ICH, anticoagulation should be discontinued immediately and rapid reversal of anticoagulation should be performed as soon as possible after diagnosis of spontaneous ICH to improve survival.

In patients with direct factor Xa inhibitor–associated spontaneous ICH, andexanet alfa is reasonable to reverse the anticoagulant effect of factor Xa inhibitors. andexanet alfa for reversal of factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban.

In patients with direct factor Xa inhibitor–associated spontaneous ICH, a 4-F PCC or activated PCC (aPCC) may be considered to improve hemostasis.

In patients with dabigatran- or factor Xa inhibitor–associated spontaneous ICH, when the DOAC agent was taken within the previous few hours, activated charcoal may be reasonable to prevent absorption of the DOAC.

In a subgroup publication of patients with factor Xa inhibitor–associated ICH, excellent or good hemostatic outcome, defined as <35% increase in hematoma volume after 12 hours, was seen in 79% of patients.

DOI: 10.1161/STR.0000000000000407

View source ↗